Philip Newsome
Title
Cited by
Cited by
Year
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
MJ Armstrong, P Gaunt, GP Aithal, D Barton, D Hull, R Parker, ...
The Lancet 387 (10019), 679-690, 2016
7862016
Pathogenesis of non-alcoholic fatty liver disease
JK Dowman, JW Tomlinson, PN Newsome
QJM: An International Journal of Medicine 103 (2), 71-83, 2010
7622010
Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling
DC Hay, J Fletcher, C Payne, JD Terrace, RCJ Gallagher, J Snoeys, ...
Proceedings of the National Academy of Sciences 105 (34), 12301-12306, 2008
4452008
Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol …
R Williams, R Aspinall, M Bellis, G Camps-Walsh, M Cramp, A Dhawan, ...
The Lancet 384 (9958), 1953-1997, 2014
4182014
Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of cellular fusion
PN Newsome, I Johannessen, S Boyle, E Dalakas, KA Mcaulay, ...
Gastroenterology 124 (7), 1891-1900, 2003
3682003
Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis
JK Dowman, JW Tomlinson, PN Newsome
Alimentary pharmacology & therapeutics 33 (5), 525-540, 2011
3532011
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort
MJ Armstrong, DD Houlihan, L Bentham, JC Shaw, R Cramb, S Olliff, ...
Journal of hepatology 56 (1), 234-240, 2012
2902012
A concise review of non-alcoholic fatty liver disease
NN Than, PN Newsome
Atherosclerosis 239 (1), 192-202, 2015
2822015
Critical review of clinical trials of bone marrow stem cells in liver disease
DD Houlihan, PN Newsome
Gastroenterology 135 (2), 438-450, 2008
2192008
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program
MJ Armstrong, DD Houlihan, IA Rowe, WHO Clausen, B Elbrønd, ...
Alimentary pharmacology & therapeutics 37 (2), 234-242, 2013
2182013
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
MJ Armstrong, D Hull, K Guo, D Barton, JM Hazlehurst, LL Gathercole, ...
Journal of hepatology 64 (2), 399-408, 2016
1932016
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper
T Boettler, PN Newsome, MU Mondelli, M Maticic, E Cordero, M Cornberg, ...
JHEP Reports, 100113, 2020
1772020
Hematopoietic stem cell trafficking in liver injury
E Dalakas, PN Newsome, DJ Harrison, JN Plevris
The FASEB Journal 19 (10), 1225-1231, 2005
1582005
Animal models of fulminant hepatic failure: a critical evaluation
PN Newsome, JN Plevris, LJ Nelson, PC Hayes
Liver Transplantation 6 (1), 21-31, 2000
1562000
Liver regeneration—mechanisms and models to clinical application
SJ Forbes, PN Newsome
Nature reviews Gastroenterology & hepatology 13 (8), 473, 2016
1512016
Isolation of primary human hepatocytes from normal and diseased liver tissue: a one hundred liver experience
RH Bhogal, J Hodson, DC Bartlett, CJ Weston, SM Curbishley, ...
PloS one 6 (3), e18222, 2011
1432011
Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease
PJ Eddowes, M Sasso, M Allison, E Tsochatzis, QM Anstee, D Sheridan, ...
Gastroenterology 156 (6), 1717-1730, 2019
1402019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ...
The Lancet 394 (10215), 2184-2196, 2019
1372019
Guidelines on the management of abnormal liver blood tests
PN Newsome, R Cramb, SM Davison, JF Dillon, M Foulerton, EM Godfrey, ...
Gut 67 (1), 6-19, 2018
1352018
Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells
SFH de Witte, F Luk, JM Sierra Parraga, M Gargesha, A Merino, ...
Stem Cells 36 (4), 602-615, 2018
1322018
The system can't perform the operation now. Try again later.
Articles 1–20